Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Regulatory Approvals for Collagen Solutions Client

10 Mar 2015 07:03

RNS Number : 9717G
Collagen Solutions PLC
10 March 2015
 

10 March 2015

 

Collagen Solutions Plc

(the "Company" or the "Group")

 

FDA 510(K) Clearance for NovaBone products

 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, is pleased to announce that its customer NovaBone Products LLC (NovaBone) has received the following 510(K) clearances from the US Food and Drug Administration (FDA). These products have been developed by NovaBone using medical grade collagen supplied by the Collagen Solutions Group. This supply is made by both Collagen Solutions and by its wholly owned subsidiary, Southern Lights Biomaterials.

 

 

Name

Product Type

FDA clearance

NovaBone Bioactive Strip

Bone graft

Orthopaedics Division

NovaBone MacroForm Bioactive

Bone graft

Orthopaedics Division

NovaTape/ NovaPlug

Wound Dressing

Dental Division

 

 

Collagen Solutions provides the highest quality, medical grade biomaterials to support medical devices and other products for regenerative medicine across an increasingly wide range of applications and clinical indications. Collagen Solutions and Southern Lights have been providing specific medical grade collagen materials to NovaBone for a number of years and is pleased to see that these collagen-based products have received FDA 510(K) clearance in the US.

 

NovaBone is a privately held biomaterials company based in Florida, USA. The Company was established in 2002 with a focus on developing bone graft substitutes based on advancements in biomedical engineering that would meet the specialised needs of orthopaedic and dental surgeons. Their products have been available for over 10 years and been used in over a million clinical applications with unparalleled success validating the safety and efficacy of the NovaBone technology.

Dr Stewart White, Chief Executive Officer of Collagen Solutions plc said: "These three FDA clearances reinforce our strategy to release the embedded value we have created in manufacturing medical grade collagen products for our customers. Once we are identified as the source of raw material and that has been included as part of the regulatory submission process, it is highly likely that we will be supplying collagen for those products for their entire life cycle. The importance of our part in our customers' future is emphasised by the recent acquisition of Southern Lights, whose separate supply to NovaBone will continue."

 

"These three products are entering the high value added area of collagen based bone grafts and wound care products which is a rapidly growing market for novel products. That is, the bone graft market in the US is estimated to be worth US$3.3 Billion, whilst the wound dressing sector is worth around US$3 Billion."

 

The US regulatory clearances achieved by NovaBone further endorse the long and strong relationship we have with our customers. Through robust partnerships we offer technical support and reliable supply to our customers who are then able to provide the necessary collagen safety information to regulatory agencies to support market clearance for their finished devices. This is a significant success for the NovaBone team."

 

 

 

 

 

 

Enquiries:

 

Collagen Solutions Plc

 

David Evans, Chairman 

Tel: 07740 084 452

Stewart White, CEO

Tel: 0141 558 2008

 

 

Zeus Capital (Nominated Adviser and Broker)

 

Ross Andrews / John Depasquale

Tel: 020 7533 7727

Alex Davies

 

Panmure Gordon & Co (Joint Broker)

 

Robert Naylor (Corporate Finance)

Maisie Atkinson (Corporate Broking)

Tel: 020 7886 2714Tel: 020 7886 2905

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or collagen@walbrookpr.com

Mike Wort

Mob: 07900 608 002

Anna Dunphy

Mob: 07876 741 001

 

 

Further information:

 

NovaBone MacroForm and Bioactive Strip devices are osteoconductive bioactive bone void fillers used for orthopaedic applications. The devices are a mixture of bioactive calcium-phospho-silicate granules and a collagen binder. The bioactive glass particulate is composed solely of elements that exist in normal bone (Ca, P, Na, Si, O). The collagen component facilitates hydration with bone marrow aspirate and handling for application to the surgical site. During absorption of the collagen binder, the particulate material remaining undergoes a time-dependent kinetic modification of the surface to stimulate osteoblast activity and guide the formation of bone across the graft site. Specifically, a series of surface reactions on the particles results in the formation of a calcium phosphate layer that is substantially equivalent in composition and structure to the hydroxyapatite found in bone mineral. This apatite layer provides scaffolding onto which the patient's new bone will grow, allowing complete repair of the defect. During healing, the graft particulate is absorbed and remodeled into new bone.

 

NovaTape & NovaPlug Dental Collagen Wound Dressings are soft, white to off-white, resorbable collagen dressings produced from cross-linked purified collagen derived from bovine hide. The dressings are intended for the management of oral wounds and sores. The thickness and pore structure of the dressing allow it to absorb fluids and blood at the defect site, thereby maintaining a moist environment. The dressings resorb within approximately 14 days of implantation.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADXGDXRGGBGUC
Date   Source Headline
20th Feb 20197:00 amRNSSale of Strategic Investment in Jellagen
18th Feb 20197:00 amRNSPresenting at the Hardman Investor Forum
4th Feb 20193:55 pmRNSVisit from Member of Scottish Parliament
31st Jan 20197:00 amRNSChondroMimetic® Update
16th Jan 20194:52 pmRNSDirector/PDMR Shareholding
15th Jan 20197:00 amRNSNew Manufacturing Agreement
7th Jan 20193:45 pmRNSAward of £1.54 million Scottish Enterprise Grant
4th Dec 20187:00 amRNSHalf-year Report
7th Nov 20187:00 amRNSInvestor presentation
5th Nov 20187:00 amRNSRealignment of Bond Repayments
23rd Oct 20187:00 amRNSTrading Update and Notice of Results
18th Oct 20187:00 amRNSBiotech and Money's Inve$tival Showcase
26th Sep 20185:04 pmRNSHolding(s) in Company
25th Sep 20183:05 pmRNSDirector/PDMR Shareholding
19th Sep 20185:01 pmRNSDirector/PDMR Shareholding
3rd Sep 201812:20 pmRNSDirector/PDMR Shareholding
3rd Sep 20187:00 amRNSBoard Appointments
3rd Sep 20187:00 amRNSExecutive Share Options Alignment
24th Aug 201811:47 amRNSDirector/PDMR Shareholding
22nd Aug 201811:40 amRNSResult of AGM
22nd Aug 20187:00 amRNSAGM Statement
21st Aug 20187:00 amRNSAppointment of Distributors in China
25th Jul 20185:21 pmRNSPosting of Annual Report and Notice of AGM
10th Jul 20187:00 amRNSFinal Results
13th Jun 20187:00 amRNSNotice of Results
8th May 20187:00 amRNSExhibiting at 18th ESSKA conference
3rd May 20183:27 pmRNSDirector/PDMR Shareholding
11th Apr 20187:00 amRNSDirector/PDMR Shareholding
10th Apr 20187:00 amRNSAppointment of Chief Business Officer
6th Apr 20189:31 amRNSDirector/PDMR Shareholding
4th Apr 20187:00 amRNSTrading update
28th Mar 20187:00 amRNSProposed restructuring of New Zealand operations
1st Mar 20187:00 amRNSConference attendance
26th Feb 20187:15 amRNSHardman & Co: Nearing first proprietary product
22nd Feb 20181:00 pmRNSDirector/PDMR Shareholding
21st Feb 20187:00 amRNSPositive results of ChondroMimetic Clinical Study
15th Feb 20187:00 amRNSChina update
6th Feb 20187:00 amRNSInvestor presentation
20th Dec 201711:55 amRNSChondroMimetic® Update
19th Dec 20173:49 pmRNSHardman Research: Targeting long-term growth
18th Dec 20177:00 amRNSDirectorate Change
14th Dec 20177:00 amRNSAppointment of Chief Financial Officer
5th Dec 20177:00 amRNSHalf-year Report
27th Nov 20174:41 pmRNSSecond Price Monitoring Extn
27th Nov 20174:35 pmRNSPrice Monitoring Extension
26th Oct 20177:00 amRNSTrading update and notice of results
21st Sep 20171:28 pmRNSHardman Research: Engineering towards CE Mark
21st Sep 20177:00 amRNSStudy Update Patient Assessments Completed
18th Sep 20177:00 amRNSPresenting at the Hardman Investor Forum
12th Sep 20177:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.